Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | HK1 | P19367 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23506033 | 0.85 | CYP1A2 (0.52) | CYP1A2CYP2D6CYP2C19CLK4CYP3A4 | |
| SCHEMBL417328 | 0.82 | CLK4 (0.52) | CYP1A2CYP2D6CYP2C19CLK4CYP3A4 | |
| SCHEMBL248683 | 0.82 | ELANE (0.50) | L3MBTL1KMT2AMEN1ALDH1A1HSD17B10 | |
| SCHEMBL31119295 | 0.74 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP2C19CLK4CYP3A4 | |
| SCHEMBL2128197 | 0.74 | MEN1 (0.62) | CYP1A2CYP2D6CYP2C19CLK4CYP3A4 | |
| Pyrimidine SCHEMBL28720905 | 0.74 | CACNA1C (0.39) | POLBKMT2AMEN1ALDH1A1MAPK1 | |
| SCHEMBL19692262 | 0.73 | ALDH1A1 (0.33) | POLBALDH1A1DYRK1A | |
| SCHEMBL12336997 | 0.73 | KDM4E (0.47) | CLK4ALOX15POLBL3MBTL1KMT2A | |
| SCHEMBL31119275 | 0.72 | CYP1A2 (0.45) | CYP1A2CYP2D6CYP2C19CLK4CYP3A4 | |
| SCHEMBL3948160 | 0.72 | ALDH1A1 (0.77) | CYP1A2CYP2D6CYP2C19CLK4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556081-B1 | A CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | INST CHEMII BIOORGANICZNEJ PAN (PL) | 2021-06-16 | — | — | EP | disclosed |
| EP-2556081-B1 | A CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | INST CHEMII BIOORGANICZNEJ PAN (PL) | 2021-06-16 | — | — | EP | disclosed |
| US-9040490-B2 | Cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2015-05-26 | — | — | US | disclosed |
| US-9040490-B2 | Cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2015-05-26 | — | — | US | disclosed |
| US-9040490-B2 | Cytosine analogue, a method of preparation of a cytosine analogue, a DNA methyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2015-05-26 | — | — | US | disclosed |
| US-20120322755-A1 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2012-12-20 | — | — | US | disclosed |
| US-20120322755-A1 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2012-12-20 | — | — | US | disclosed |
| US-20120322755-A1 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | INSTYTUT CHEMII BIOORGANICZNEJ PAN (PL) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322755-A1 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION | DNMT1, DIMT1, TPMT | CYP1A2 1451/4885CYP2D6 891/4885CYP2C19 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.